Welcome to our dedicated page for Anixa Biosciences news (Ticker: ANIX), a resource for investors and traders seeking the latest updates and insights on Anixa Biosciences stock.
Anixa Biosciences, Inc. (NASDAQ: ANIX) is a clinical-stage biotechnology company dedicated to the treatment and prevention of cancer. The company's core focus includes developing vaccines and therapies aimed at critical unmet needs in oncology. Anixa's innovative approach involves both diagnostics and therapeutics to detect and treat cancer at its most curable stages.
The company's therapeutic portfolio features a pioneering ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center. This program utilizes a novel CAR-T technology, known as chimeric endocrine receptor T-cell (CER-T), which targets the follicle-stimulating hormone receptor (FSHR) specifically expressed on ovarian cells. This technology represents a potential breakthrough in treating solid tumors, a challenge for traditional CAR-T therapies.
Anixa is also advancing a unique vaccine portfolio in collaboration with Cleveland Clinic, targeting the prevention of breast cancer, specifically triple-negative breast cancer (TNBC), the most aggressive form of the disease, as well as ovarian cancer. These vaccine technologies focus on immunizing against
Anixa Biosciences (NASDAQ: ANIX) announced a presentation of its breast cancer vaccine trial at the ASCO Annual Meeting on June 3-7, 2022. The presentation, led by Dr. George Thomas Budd of Cleveland Clinic, focuses on a Phase 1 trial of an alpha-Lactalbumin vaccine for patients with operable triple-negative breast cancer (TNBC). With TNBC being a significant challenge in oncology, accounting for a high percentage of breast cancer deaths, Anixa’s approach targets proteins unique to this cancer type. The vaccine aims to activate the immune system for early tumor prevention.
On April 6, 2022, Anixa Biosciences (NASDAQ: ANIX) announced that Dr. José Conejo-Garcia will present its ovarian cancer CAR-T technology at The 4th International Workshop on CAR-T on April 29, 2022. He will chair a panel discussing Chimeric Endocrine Receptor T-cell (CER-T) technology for treating ovarian cancer. A Phase 1 clinical trial using this innovative therapy has recently begun at Moffitt Cancer Center. Anixa holds an exclusive worldwide license for this technology.
Anixa Biosciences (NASDAQ: ANIX) has launched a Phase 1 trial for its innovative chimeric endocrine receptor T-cell (CER-T) therapy targeting ovarian cancer at Moffitt Cancer Center. This trial aims to assess the safety and effectiveness of CER-T therapy, which uniquely targets the follicle stimulating hormone receptor (FSHR), exclusively expressed on ovarian cells. With an exclusive license for this technology developed at the Wistar Institute, Anixa partners with leading scientists to enhance treatment options for recurrent, chemo-resistant ovarian cancer, potentially revolutionizing therapy for solid tumors.
Anixa Biosciences, Inc. (NASDAQ: ANIX) announced its participation in the 2022 Virtual Growth Conference hosted by M-Vest from March 28-30, 2022. The presentation will be led by Mike Catelani, the Chief Operating Officer and Chief Financial Officer, who will provide an overview of the company's business and program updates. Anixa focuses on developing cancer treatments and vaccines, including an innovative CAR-T immunotherapy and vaccines targeting triple negative breast cancer and ovarian cancer. For more details, visit www.anixa.com.
Anixa Biosciences (NASDAQ: ANIX) has received a Decision to Grant a patent from the Japanese Patent Office for its ovarian cancer vaccine technology, developed at Cleveland Clinic. This vaccine targets the anti-Müllerian hormone receptor 2 (AMHR2-ED), potentially preventing ovarian cancer, particularly in post-menopausal women. Preclinical studies are ongoing at the National Cancer Institute (NCI), with promising data previously published. Anixa's innovative approach aims to provide a preventative measure against one of the most aggressive cancers, enhancing its therapeutic portfolio.
Anixa Biosciences (NASDAQ: ANIX) announced a significant breakthrough with its partner MolGenie GmbH in developing a new compound that shows greater potency than nirmatrelvir, the primary component of Pfizer's COVID-19 treatment, PAXLOVID. The compound targets the main protease (Mpro) of SARS-CoV-2, which is preserved across various virus variants. Anixa's compounds are undergoing further testing, including cellular assays and animal studies, with potential for improved oral therapies against COVID-19.
Anixa Biosciences (NASDAQ: ANIX) is set to participate in two significant investor conferences: the LifeSci Partners 11th Annual Corporate Access Event on January 5-7, 2022, and the H.C. Wainwright BioConnect Conference from January 10-13, 2022. CEO Dr. Amit Kumar will address a panel on cancer vaccines on January 7 at 2:00 pm ET. Investors can request 1x1 meetings during both events. Anixa is focused on innovative cancer therapies and COVID-19 treatments, including a vaccine for triple negative breast cancer (TNBC).
Anixa Biosciences (NASDAQ: ANIX) has partnered with MolGenie to analyze compounds aimed at treating COVID-19. Recent findings suggest these compounds could be effective against the Omicron and Delta variants of SARS-CoV-2. The focus is on developing inexpensive, orally-administered therapies that can inhibit the virus’s main protease (Mpro). The compounds have shown promising efficacy and potency in initial testing. Anixa continues to adapt its strategy in response to emerging COVID-19 variants to support global health efforts.
Anixa Biosciences (NASDAQ: ANIX) has started dosing patients in a Phase 1 study of a vaccine aimed at preventing triple-negative breast cancer, a particularly aggressive cancer type. Conducted in partnership with Cleveland Clinic, the study is funded by the U.S. Department of Defense and will involve 18 to 24 patients at high risk for recurrence. Participants will receive three doses of the vaccine over six weeks. The study aims to assess the maximum tolerated dose and immune response, with completion expected by Q3 2022. The vaccine uses a unique approach targeting specific proteins associated with breast cancer.
Anixa Biosciences (NASDAQ: ANIX) has received a patent from the China National Intellectual Property Administration (CNIPA) for its Chimeric Antigen Receptor-T cell (CAR-T) technology, known as Chimeric Endocrine Receptor T-cell (CER-T) therapy. This innovation targets the follicle stimulating hormone receptor and is aimed at treating ovarian cancer. The technology has also received a Notice of Allowance from the U.S. Patent and Trademark Office. Clinical trials are expected to commence by year-end, with potential applications for other solid tumors as well.
FAQ
What is the current stock price of Anixa Biosciences (ANIX)?
What is the market cap of Anixa Biosciences (ANIX)?
What does Anixa Biosciences specialize in?
What are the key components of Anixa's therapeutic portfolio?
What recent achievements has Anixa Biosciences announced?
Who are some of Anixa Biosciences' key collaborators?
How does Anixa's CER-T technology differ from traditional CAR-T therapies?
What is unique about Anixa's cancer vaccine technology?
Which forms of cancer are Anixa's vaccines targeting?
What are some recent clinical trial results from Anixa?
Does Anixa Biosciences participate in industry conferences?
Where can I find more information about Anixa Biosciences?
